Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0I6QZ
|
||||
Drug Name |
Org-37663
|
||||
Synonyms |
Org-37663
|
||||
Indication | Unspecified | Investigative | [1559976] | ||
Target and Pathway | |||||
Target(s) | Estrogen receptor | Target Info | Modulator | ||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
Signaling events mediated by HDAC Class II | |||||
Plasma membrane estrogen receptor signaling | |||||
LKB1 signaling events | |||||
Regulation of Telomerase | |||||
ATF-2 transcription factor network | |||||
AP-1 transcription factor network | |||||
FOXM1 transcription factor network | |||||
Validated nuclear estrogen receptor alpha network | |||||
Signaling mediated by p38-alpha and p38-beta | |||||
FOXA1 transcription factor network | |||||
References | |||||
Ref 1559976 | The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.Arthritis Rheum.2010 Feb;62(2):351-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.